ARH-77細(xì)胞

細(xì)胞類型： B**細(xì)胞

是否是腫瘤細(xì)胞： 0

物種來源： 人

數(shù)量： 大量

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

年限： 33 years

細(xì)胞形態(tài)： **樣

**類型： IgG1; kappa light chain

ARH-77細(xì)胞運(yùn)輸方式： 凍存運(yùn)輸

器官來源： 外周血

ATCC Number： CRL-1621?

相關(guān)**： 其他**

Designations: ARH-77

Depositors: BD Drewinko

Isotype: IgG1; kappa light chain

Biosafety Level: 2 [Herpesvirus; cells contain EBV ]

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Homo sapiens

Morphology: ARH-77細(xì)胞lymphoblast

Source: Organ: peripheral blood

Disease: plasma cell leukemia

Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Antigen Expression: CD11a +; CD19 +; CD20 +; CD28 +; CD38 -; CD49e +

DNA Profile (STR): Amelogenin: X

CSF1PO: 6,10

D13S317: 11,13

D16S539: 9,13

D5S818: 10,13

D7S820: 7,12

THO1: 8,9.3

TPOX: 8

vWA: 17

ARH-77細(xì)胞Age: 33 years

Gender: female

Ethnicity: Caucasian

Comments: The ARH-77 cell line was established from the peripheral blood of a patient suffering from IgG plasma cell leukemia.

Although established from cells taken from a patient with a plasma cell leukemia, this line has been shown to be an EBV-transformed B lymphoblastoid cell line. [43270]

The cells are positive for Epstein-Barr nuclear antigen(EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +). [58044]

The line has been cured of a previous mycoplasma infection.

LICR-LON-HMy2 (HMy2), a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), was irradiated and selected for class I loss to establish the HMy2.C1R (ATCC CRL-1993) cell line. [26111]

Subsequently, C1R-neo (ATCC CRL-2369), C1R-sB7 (ATCC CRL-2370), and C1R-B7 (ATCC CRL-2371) were established by transfection of the HMy2.C1R cell line. [23312]

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 viable cells/ml and subculture at 1 X 10 exp6 cells/ml.

Medium Renewal: ARH-77細(xì)胞Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%

Storage temperature: liquid nitrogen apor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

derivative:ATCC CRL-1993

References: 1089: Burk KH, et al. Establishment of a human plasma cell line in vitro. Cancer Res. 38: 2508-2513, 1978. PubMed: 566614

1651: Cote RJ, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80: 2026-2030, 1983. PubMed: 6572959

23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

26111: Edwards PA, et al. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur. J. Immunol. 12: 641-648, 1982. PubMed: 7140810

26112: . . Proc. Am. Assoc. Cancer Res. 19: 211, 1978.

43268: Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375

43270: Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762

58044: Drewinko B, et al. ARH-77細(xì)胞ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer 54: 1883-1892, 1984. PubMed: 6090003